Our Science – Xi Website
Liqiang Xi, M.D.
Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.
At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing. In addition to research and development of new molecular tests that support molecular diagnostics and personalized cancer therapies, Dr. Xi's research interests currently focus on analysis of circulating tumor DNA in melanoma to measure the immunotherapy response, and targeted mutational analysis of uncommon types of lymphoma.
This page was last updated on 5/27/2014.